^
Association details:
| Biomarker: | HER-2 negative |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | capecitabine (Thymidylate synthase inhibitor) + cyclophosphamide (Alkylating agent) + methotrexate (THF dehydrogenase inhibitor, Dihydrofolic acid reductase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer
Excerpt:
...with most recent breast or axillary surgery 10% by IHC) and/or progesterone receptor (PR)-positive (> 10% by IHC), HER2-negative by IHC or FISH according to 2018 ASCO-CAP guidelines....
Trial ID:
Source:
Title:
EFFICACY AND TOLERABILITY OF METRONOMIC CHEMOTHERAPY (mChT) WITH CYCLOPHOSPHAMIDE, METHOTREXATE AND CAPECITABINE (CMX) IN PATIENTS WITH HEAVILY PRETREATED ADVANCED BREAST CANCER. RESULTS FROM A MULTICENTER RETROSPECTIVE STUDY.
Published date:
12/02/2023
Excerpt:
This is a multicenter, retrospective study that included patients with HER2-negative ABC who received treatment with CMX (capecitabine 500 mg thrice daily, methotrexate 2.5 mg twice a week, and cyclophosphamide 50 mg daily)….Objective response rate was 20.8% and disease control rate was 54.2%. Median progression-free survival was 6.1 months (95% confidence interval [CI] 95%; 4.3 - 12.4) and median overall survival was 12.3 months (95% CI; 6.8 - 24.7).
